Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

NCI

In the precision medicine era, the line between products and services is blurred

Precision and personalised medicines are more than products, they are services in their own right. So, how should pharma approach this uncharted territory to ensure targeted therapies work for patients?

Blue Latitude Health

- PMLiVE

Bristol-Myers Squibb’s revenues rise on Celgene acquisition

Sales of immunotherapy Opdivo decreased due to COVID-19 impact

- PMLiVE

Gilead makes a play for novel cancer drug with Tizona deal

Pharma company continues oncology biotech spending spree

- PMLiVE

Medical affairs – a strategic function for scientific engagement

The shift in dynamics between medical affairs and commercial teams

Bedrock Healthcare Communications

- PMLiVE

Mobile ethnography means no delays to the PoTS LIVE charity project

The team at Origins Insights are excited to introduce PoTS LIVE, our pro bono mobile ethnography project. Remarkably, the project marches on with its fieldwork phase even with the current...

Bedrock Healthcare Communications

- PMLiVE

Mergers and acquisitions: agents for change

Getting the best from your agency in a disruptive time

Bedrock Healthcare Communications

- PMLiVE

GlaxoSmithKline reportedly looking to sell select antibiotic brands

Sale would fund R&D efforts in other key focus areas such as oncology

- PMLiVE

Gilead swoops on Forty Seven with $4.9bn all-cash deal

Takeover is latest in a string of billion-plus deals signed by Gilead

- PMLiVE

Boehringer links up with Trutino for cancer R&D

Collaboration agreement will focus on cytokine treatments

- PMLiVE

Celgene’s Revlimid scores NICE approval in follicular lymphoma

New ‘chemotherapy-free’ treatment for patients with limited options

- PMLiVE

Bedrock Group celebrates a trio of new hires

Bedrock Group is gearing up for a year of incredible growth with the hire of two new Strategic Solutions Directors as well as an additional Account Manager.

Bedrock Healthcare Communications

- PMLiVE

FDA begins speedy review of BMS’ CAR-T liso-cel

Agency sets target action date of 17 August for final decision

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links